Podcasts about Poolbeg

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington talked with Proactive's Stephen Gunnion about the company's interim results and key clinical milestones. Skillington highlighted that Poolbeg ended June with £10 million in cash, supported by an upsized and oversubscribed £4.87 million fundraise earlier in the year. He said this extends the company's cash runway into 2027, providing a strong foundation for advancing upcoming trials. One of the company's main focuses is POLB 001, which is being developed to prevent cytokine release syndrome in patients undergoing cancer immunotherapies. “We expect to have interim data in the summer of 2026 that we can start sharing with our pharma colleagues,” Skillington noted. The trial will take place at the Christie NHS Foundation Trust under Dr Emma Searle, with support from Accelerating Clinical Trials (ACT). Skillington also discussed Poolbeg's oral GLP-1 program, developed in partnership with AnaBio Technologies. This program uses an encapsulation technology to allow oral delivery of GLP-1, currently given mostly by injection. A rapid proof-of-concept trial is planned under Prof Carel le Roux at the University of Ulster, with data expected in the first half of 2026. Looking ahead, Skillington said Poolbeg is entering a “catalyst-rich period” with multiple updates expected that could attract pharmaceutical partners. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and turn on notifications to stay informed. #PoolbegPharma #POLB001 #GLP1 #CancerImmunotherapy #Biotech #ClinicalTrials #Oncology #ObesityTreatment #DrugDevelopment #PharmaInnovation

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble talked with Proactive's Stephen Gunnion about the company's upcoming Phase 2a trial for POLB001. Tremble explained that Poolbeg has partnered with Accelerating Clinical Trials (ACT) in the UK to conduct the study, which will be led by Dr Emma Searle at the University of Manchester and the NHS Christie Foundation Trust. The Christie is one of Europe's largest cancer centres, treating more than 60,000 patients annually, and will act as the lead site. Tremble emphasised, “We've been really fortunate and feel quite blessed that we found a massive amount of interest in participating on this trial.” The trial will be a single-arm, open-label Phase 2a study involving approximately 30 patients. With sufficient supply of both POLB001 and the required bispecific antibody, Poolbeg expects to generate data throughout 2026, with a focus on safety and efficacy. Skillington noted the wider potential for POLB001 in cancer immunotherapy. He said that reducing cytokine release syndrome could allow treatments to move beyond specialist centres into community hospitals. “We feel POLB001 can do that,” he added, describing the market opportunity as greater than $10 billion. He also highlighted that the company holds FDA orphan drug designation for POLB001 and has a cash runway into 2027, positioning Poolbeg to achieve multiple milestones and advance partnering discussions. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and enable notifications for future content. #PoolbegPharma #POLB001 #CancerResearch #Immunotherapy #ClinicalTrials #Biotech #Oncology #BloodCancer #PharmaNews #DrugDevelopment

Watch on YouTube Poolbeg Pharma CEO Jeremy Skillington and Liam discuss the execution plan for their upcoming Phase 2a trial of POLB 001, a promising candidate in cancer immunotherapy. They detail the trial design, the selection of clinical partners, and the potential impact of the drug. Jeremy also outlines what investors can expect in the near term as the programme advances.

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company's ambitious pipeline and strategic direction.

Poolbeg Pharma, named after the infamous Red & white towers has been working on some very exciting new ideas including a new cancer immunity drug and a potential weight loss tablet. But most early drug developments fail to make it to the final round of testing on humans because it's so risky and so expensive. And what does a pharma company like Poolbeg make of the EU-US trade deal with its 15% tariffs thus far? Jeremy Skillington, is the chief executive of Poolbeg pharma and joined Joe Lynam on the show this morning.

Nicola Kearns made it clear the anger parents are feeling about the rise in college fees. Siobhan O'Neill White is another unhappy parent when if comes to railway travel's fairer fares. Monica McGuinness has a three book deal with Poolbeg, as her first novel Crowfield House is published. David Sheehan looked ahead to the weekend's sporting action, classic comedy and a TV theme completed our line up this afternoon. Hosted on Acast. See acast.com/privacy for more information.

Watch on YouTube Following on from its £4.865 million raise last week, Poolbeg #POLB has announced that it has received FDA Orphan Drug Designation for POLB 001. Chief executive Jeremy Skillington joins us to tell us what it all means.

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce a significant milestone in the company's clinical development strategy: the U.S. Food and Drug Administration has granted Orphan Drug Designation to POLB 001, Poolbeg's innovative oral therapy aimed at preventing Cytokine Release Syndrome caused by T-cell engager bispecific antibody immunotherapies. POLB 001, an oral small molecule inhibitor of the IL-1 receptor, is designed to modulate the inflammatory response without suppressing the underlying anti-cancer immune activation. The FDA's Orphan Drug Designation recognizes the potential of POLB 001 to address a rare but serious medical condition, affecting fewer than 200,000 individuals annually in the United States. This designation confers a range of developmental and commercial incentives including seven years of U.S. market exclusivity post-approval, waiver of certain FDA fees, such as the Prescription Drug User Fee Act or PDUFA application fees and others. The company plans to initiate a Phase 2a clinical trial in the second half of 2025, marking the next step in evaluating POLB 001's efficacy and safety in a controlled setting. Poolbeg anticipates completing interim analysis in the first half of 2026, with topline data expected in the second half of 2026. With the Orphan Drug Designation in hand, Poolbeg is now well-positioned to advance discussions with potential partners and stakeholders as it progresses toward its clinical milestones. #proactiveinvestors #poolbegpharma #aim #polb #OrphanDrug #POLB001 #FDAApproval #CytokineReleaseSyndrome #CancerTherapy #BiotechNews #Immunotherapy #ClinicalTrials #PharmaInvesting

Watch on YouTube Vox Markets caught up with Poolbeg Pharma #POLB CEO Jeremy Skillington at the Master Investor Show, where he discussed the company's exciting progress in 2024. Jeremy highlighted strong investor engagement and shared updates on Poolbeg's two lead programmes.

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce the company's unaudited interim results for the first half of 2024, highlighting strong progress with its lead development candidate, POLB 001. As of 30 June 2024, the company reported a cash balance of £10.1 million, showcasing its prudent financial management and ability to support ongoing development initiatives. Skillington emphasized that POLB 001 is on track, with robust data demonstrating its efficacy in reducing cancer immunotherapy-induced cytokine release syndrome (CRS) in an in vivo animal model. This strengthens the company's patent portfolio, with the U.S. Patent Office recently granting Poolbeg a new patent for its Immunomodulator II, covering a class of drugs, including POLB 001, aimed at treating or preventing hypercytokinemia (cytokine storm) across a range of diseases. This patent approval enhances Poolbeg's ability to expand its intellectual property and attract potential partners. Poolbeg Pharma is actively engaging with multiple potential partners to further develop and commercialize POLB 001. Additionally, the company signed an exclusive 12-month option agreement for tPTX, a novel topical muco-adherent treatment for oral ulcers in patients suffering from Behçet's Disease. The treatment holds significant potential, with FDA Fast Track Designation, Orphan Drug Designation, and a possible 505(b)(2) approval pathway in the U.S., indicating its promising market prospects. Skillington emphasized Poolbeg's commitment to advancing its pipeline while maintaining strong financial discipline, positioning the company for future growth and partnerships in the biotech sector. #proactiveinvestors #poolbegpharma #aim #polb #RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors

Following their H1 interims for 2024, Vox Markets talks to their CEO Jeremy Skillington

John, sailing enthusiast and Commodore of the Irish Cruising Association told Brendan all about the annual Three Bridges Rally. It's when three of the bridges on the Liffey will open and lift - allowing a parade of some 45 boats to sail up-river from Poolbeg up to the Matt Talbot bridge. It's on at 3pm on the 7th of September.

Painting work on the Poolbeg Chimneys in Dublin begins this week. Having been immortalised in print, on t-shirts and even coffee mugs, why are the towers so iconic, and do they continue to divide opinion?Joining guest host Mairead Ronan to discuss is Emma Gileece, Architectural Historian.

Painting work on the Poolbeg Chimneys in Dublin begins this week. Having been immortalised in print, on t-shirts and even coffee mugs, why are the towers so iconic, and do they continue to divide opinion?Joining guest host Mairead Ronan to discuss is Emma Gileece, Architectural Historian.

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD present an overview of their current programmes and opportunities, focussing on POLB 001, data, exclusive option agreement and their AI-powered research using human viral challenge data Headquartered in London and publicly traded on the London Stock Exchange & the OTC Markets in the US AIM: POLB | OTCQB: POLBF Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines that address critical unmet medical needs. They are focused on strategically commercialising approved and marketed drugs to fund the development of a robust pipeline of innovative products, driving significant value creation. Jeremy Skillington began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech, he was responsible for executing over 40 licencing, investment and collaboration transactions.  Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH. Jeremy joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September 2020 for €380M (£325M) upfront and significant downstream milestones.  Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D.  He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck. https://www.share-talk.com/poolbeg-pharma-plc-chief-executive-officer-jeremy-skillington-phd-talking-to-zak-mir/

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD and Chief Business Officer, David Allmond present an overview of their current programmes and opportunities, focussing on POLB 001, their oral delivery platforms, exclusive option agreement and their AI-powered research using human viral challenge data, followed by a Q&A session. Jeremy Skillington PhD, Chief Executive Officer 00:16 - Introduction 03:06 - Programmes 04:08 - 2024 highlights David Allmond, Chief Business Officer 05:03 - POLB 001 & CRS 08:01 - POLB 001's efficacy 10:15 - POLB 001 Market Opportunity 14:17 - POLB 001 support 16:12 - Topical PTX & Behçet's Disease 18:36 - Topical PTX 12 month option 20:29 - Topical PTX Phase 2 trial Jeremy Skillington PhD, Chief Executive Officer 22:05 - Topical PTX outlook 22:48 - Oral delivery platform 25:02 - Artificial Intelligence programmes 28:13 - Investment case 29:30 - Q&A Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. For more information, please go to www.poolbegpharma.com  or follow on Twitter and LinkedIn @PoolbegPharma.

WAKE gets musical! We welcome our first guest, musical genius Meg Logue, who has arranged and performed potentially the most melodious cover ever of The Ballad of Persse O'Reilly. We discuss gravelly voiced Irishmen, German opera, singing at wakes, and agree that we'd all like a sip of whatever Poolbeg's on. This week's readers: Meg Logue, Toby Malone Progress: 47 pages complete, 581 pages to go; 7.4% read. For early drops, community and show notes, join us at our free Patreon, at ⁠⁠⁠⁠⁠patreon.com/wakepod⁠⁠⁠⁠⁠. We welcome comments from everyone: even, nay, especially, the dreaded purists. Come and "um actually" us!

We spoke to travel editor Eoghan Corry about the implications for Red Bull after they sent three skydivers in between the Poolbeg Towers at wind speeds of 253 km/h.

Emma Gilleece, Architectural Historian.

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications. The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001. The company has also applied for patents concerning dosage regimens based on results from their recent LPs trial, aiming to protect innovations and maintain a competitive edge in the pharmaceutical market. This strategic IP protection is crucial for safeguarding the company's products and ensuring shareholder value, particularly as they seek partnerships to further develop POLB 001. #PoolbegPharma, #POLB001, #Immunomodulator, #USPatentOffice, #IntellectualProperty, #Pharmaceuticals, #CytokineStorm, #Hypercytokinemia, #PatentGranted, #DrugDevelopment, #MedicalInnovation, #CancerImmunotherapy, #InfluenzaTreatment, #PharmaIndustry, #JohnMcEvoy, #HealthcareNews, #Biotech, #ClinicalTrials, #PharmaPartnerships, #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Jeremy Skillington, CEO of Poolbeg Pharma (POLB) talks Vox Markets through a landmark year that has seen the innovative biopharma company make huge strides progressing its treatments, opening up new markets, and strengthening its team - all whilst retaining its strong balance sheet thanks to disciplined capital allocation.

Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Coté CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulcers in patients with Behçet's disease, a rare and debilitating condition. Skillington said the move is aligned with Poolbeg's strategic focus on rare and orphan diseases. Coté, with an extensive background in orphan drug approvals from his time at the FDA, highlighted the potential of the drug given its unique formulation and unmet need in the market. He explained the severe impact of Behçet's disease, underscoring the innovative potential of their topical treatment in improving the quality of life for those affected. Both CEO expressed optimism about their collaboration's potential to fast-track this novel treatment to market, leveraging Poolbeg's and Silk Road's combined expertise. Furthermore, Skillington provided insights into Poolbeg's financial health and strategic developments over the past year, mentioning a robust cash position of £12.2 million at the end of 2023. He emphasised the company's disciplined capital allocation and the expansion of its intellectual property portfolio. Looking ahead, Skillington outlined Poolbeg's focus on progressing its pipeline, particularly ongoing projects like POLB001 in the oncology sector, addressing cytokine release syndrome—a critical side effect in cancer immunotherapies. #PoolbegPharma, #SilkRoadTherapeutics, #orphanDrug, #BehçetsDisease, #PROG001, #cytokineReleaseSyndrome, #pharmaceuticals, #drugDevelopment, #orphanDiseases, #clinicalTrials, #FDA, #drugApproval, #healthcare, #medicalInnovation, #patientCare, #biotech, #pharma, #strategicPartnership, #marketAccess, #intellectualProperty, #capitalAllocation Headlines: New Topical Treatment for Behçet's Disease in Development by Poolbeg and Silk Road Exciting Developments in Rare Disease Treatment: Poolbeg Pharma's Latest Updates #ProactiveInvestors #InsertCompanyName #InsertStockMarket LEAVE THESE IN AS STANDARD & ADD ANY YOU FEEL ARE RELEVENT #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

As the Biologist, Researcher and two-time Pulitzer Prize winner, Edward Osborne Wilson stated, “In our attempt to make scientific discoveries every problem is an opportunity and the more difficult the problem the greater will be the importance of its solution”. With that in mind welcome to this latest episode in the Investing Matters podcast series with the hugely talented and globally respected, Dr. Jeremy Skillington, the Scientist, Biotechnologist, Entrepreneur and CEO of London AIM listed, £50 million market cap Poolbeg Pharma. Poolbeg Pharma plc is a biopharmaceutical company that is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases. Jeremy whose father worked at a Pfizer manufacturing plant in Cork, Ireland, “Always had an interest in the sciences”. Which would first take him to Munster Technical University where he attained his Diploma in Food Science and Technology, followed by his Biochemistry, Bachelor of Science Degree with Honours from the University of Galway (UoG). He also later attained his Biochemistry PhD from UoG. After completing his PhD Jeremy did Postdoctoral research at the University of California, San Francisco for three years before entering the Biotech industry in the Business Development group at Genentech in California in 2002. Throughout his time at Genetech up to 2009 Jeremy played a significant role in executing over forty licensing, investment and collaborations with biotech companies globally. Jeremy recalls, “how he learned so much from this hard-working, driven, smart but friendly and supportive Genetech Business Development team. With two stand out people in those early days, being his hiring manager, Dr Jonathan Lewis, an Oxford educated Immunologist and investment banker, and an industry veteran, Dr Jack Obijeski. Who both took him under their wings and showed him the biotech ropes. Since returning to Ireland in 2009, Dr Jeremy Skillington has crammed in an awful lot globally, including investing in the Medtech space, being the third employee of the very significant Irish biotech firm Inflazome, which after a mere four years achieved a landmark exit in September 2020 when it was purchased by Swiss drug giant Roche, This after Inflazome's leadership team with Jeremy heading up its business development had driven its phenomenal success. Then in 2021 he took “the call“ from seasoned serial entrepreneur Cathal Friel to become the CEO of Poolbeg Pharma. Jeremy has held that role since mid-2021 prior to Poolbeg Pharma's AIM listing in July 2021. Dr Jeremy Skillington, CEO of Poolbeg Pharma now has over twenty-one years' experience in the biotech industry, please listen to his fascinatingly insightful Investing Matters interview. As he shares insights on the global and Irish MedTech, Pharma, Biotech industry, angel investing via the Medtech Syndicate, the importance having “skin in the game”, leading and investing his money into Poolbeg Pharma's long-term potential, due to its world class leadership team and robust pipeline of innovative products and much more.

Cathal Friel a serial entrepreneur having started hVIVO and Poolbeg pharma. His latest venture European Green Transition floated on the AIM stock market in London yesterday and values the company at around €17m.EGT hopes to find rare Earth metals which can be used to transition away from fossil fuels. Cathal joined Joe in studio this morning to chat about his latest venture.

Jeremy Skillington and David Allmond of Poolbeg Pharma, discuss with David Buik about the company's journey, market position, and future prospects. They touch upon Poolbeg's establishment, market performance, recent developments, strategic focus on rare diseases, and utilisation of artificial intelligence in drug development. The conversation also delves into Poolbeg's unique offerings, such as its oral delivery programs and differentiation in the competitive landscape of biopharma.

hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions while emphasizing his commitment to remain a long-term, supportive shareholder despite this sale. Friel, who co-founded hVIVO (formerly known as Open Orphan) in 2017, highlighted the company's significant growth and his active involvement in its operations and strategic direction. He mentioned his 25-year experience in mergers and acquisitions (M&A) and his confidence in the company's ability to surpass its medium-term revenue target of £100 million, partly through strategic M&A activities. Additionally, Friel talked about his new role as Executive Chairman at Poolbeg, a company associated with hVIVO, assuring that this would not diminish his involvement with hVIVO. He shared his enthusiasm for the future of both companies, underscoring his role in identifying market opportunities and assembling high-performing teams to capitalize on them. #hVIVO #PoolbegPharma #CathalFriel #PharmaInvesting #Biotech #MergersAndAcquisitions #InvestmentBanking #HealthcareInnovation #StockMarket #Pharmaceuticals #ExecutiveLeadership #GrowthStrategy #ShareholderValue #BiotechStocks #InvestmentOpportunities #PharmaNews #UKBiotech #StrategicGrowth #InvestorRelations #CorporateStrategy #HealthcareStocks #proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another company he founded. With the addition of key former Amryt leadership team members to Poolbeg, Friel said he is optimistic about the company's aggressive growth prospects and is focused on share price appreciation. The chairman also explained the rational for the sale of shares in hVIVO PLC by directors, including himself. Friel, who has a rich background in mergers and acquisitions (M&A) and investment banking, said the decision was driven by strong institutional demand for hVIVO stock. Despite selling a small portion of his stake, he affirmed his long-term commitment to the company, highlighting its robust growth, profitability, and cash generation under current management. He also revealed plans to increase his stake in Poolbeg, indicating confidence in the company's potential and his commitment to driving shareholder value. #PoolbegPharma #CathalFriel #PharmaInvesting #Biotech #MergersAndAcquisitions #InvestmentBanking #HealthcareInnovation #StockMarket #Pharmaceuticals #ExecutiveLeadership #GrowthStrategy #ShareholderValue #BiotechStocks #InvestmentOpportunities #PharmaNews #UKBiotech #StrategicGrowth #InvestorRelations #CorporateStrategy #HealthcareStocks #proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma Plc chief business officer David Allmond joined Proactive's Stephen Gunnion with details of independent research that confirms the massive market potential for Poolbeg's POLP 001 in cancer immunotherapies. This asset is being explored for its ability to potentially prevent or treat cytokine release syndrome (CRS), a significant side effect of cancer immunotherapies. With the cancer immunotherapy market expected to reach $140 billion by 2030, POLB 001 presents an over $10 billion opportunity if successful. Additionally, Allmond elaborated on Poolbeg's increasing emphasis on rare and orphan diseases, leveraging its ongoing programs in influenza with POLB 001, obesity, metabolic conditions, and AI-driven discovery for novel targets. The company is actively considering strategies to acquire near-stage commercial or in-market products in this high unmet need, limited competition sector. This approach aligns with Poolbeg's evolution towards a commercial-stage organization, aiming to generate revenue and continue its growth trajectory. Furthermore, Allmond explained how POLB 001 fits into the rare orphan disease space, given its potential applications in orphan cancers where immunotherapies have shown success. Poolbeg's strategic pivot towards rare and orphan diseases complements its existing portfolio, aiming for a dual-track growth strategy focusing on both its current programs and commercial opportunities in the rare and orphan disease market. ‌ #PoolbegPharma #CancerImmunotherapy #RareDiseases #OrphanDiseases #Biotech #HealthcareInnovation #MedicalResearch #Pharmaceuticals #CytokineReleaseSyndrome #Immunotherapy #Biopharmaceuticals #DrugDevelopment #ClinicalTrials #PULP001 #DavidAllmond #ProactivInterview #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The ESB has opened a major battery plant at its Poolbeg site in Dublin which will add 75MW (150MWh) of fast-acting energy storage to help provide grid stability and deliver more renewables on Ireland's electricity system. This latest battery energy storage system (BESS), currently the largest site of its kind in commercial operation in Ireland, is part of ESB's pipeline of projects which are being delivered at sites in Dublin and Cork - representing an investment of up to €300m. These high-capacity batteries can store excess renewable energy for discharge when required, and in doing so, help to support Ireland in reaching its ambitious climate targets by 2030 and ESB in achieving its Net Zero by 2040 strategy. This project, operational since late November 2023, has a capability of providing 75MW of energy for two hours to Ireland's electricity system. This plant is located at ESB's Poolbeg Energy Hub in Dublin where some of the latest technologies that will support the future delivery of renewable energy including batteries, hydrogen and offshore wind will be deployed over the next decade. ESB is working with partners Fluence, as well as Irish companies, Kirby Group and Powercomm Group, in the delivery of these projects at Poolbeg, Aghada, Inchicore, and South Wall - the remainder of these projects are due to be completed this year. Eamon Ryan TD, Minister for the Environment, Climate and Communications, said: "Energy storage like this major battery plant at the ESB's flagship site in Poolbeg will be a core part of Ireland's new renewable energy transition and will play a key role in balancing our new, homegrown power supply. No electricity system can operate without a backup. In Ireland this has traditionally been provided by fossil fuel generation. Jim Dollard, ESB Executive Director, Generation and Trading, outlined how the plant will support ESB's Net Zero by 2040 target: "Today marks another important milestone for ESB as we launch our latest fast-acting grid-scale battery unit that will support grid stability and help to deliver more renewables on Ireland's electricity system. The location of this project, at our Poolbeg Energy Hub, will build on our longstanding history of innovation at the site. See more stories here.

Poolbeg Pharma PLC's newly appointed Vice President of Clinical Operations Laura Maher joined Proactive's Stephen Gunnion to discuss her role at the company. Maher detailed her responsibilities at Poolbeg, emphasizing her leadership in developing and managing clinical programs. She highlighted the importance of collaborations, both internally and with external service providers, to ensure the acquisition of quality data. Maher's significant achievements at Amryt include her pivotal role in the development and approval of Filsuvez, a treatment for Epidermolysis Bullosa (EB). She oversaw the largest-ever EB trial, leading to EMA approval in June 2022, marking it as the world's first approved treatment for EB. Despite initial FDA rejection, her perseverance led to eventual FDA approval in December 2023. Her extensive background in clinical research and operations, beginning with a research master's degree and experience in various roles across academia and small pharma companies, informs her approach at Poolbeg. Maher expressed her enthusiasm for working in a dynamic environment like Poolbeg, particularly excited about their cancer immunotherapy and cytokine release syndrome projects. #PoolbegPharma #ClinicalOperations #LauraMaher #PharmaceuticalIndustry #ClinicalTrials #DrugApproval #EpidermolysisBullosa #EBTreatment #FDAApproval #EMAAuthorization #AmrikPharma #Philserv #HealthcareInnovation #CancerImmunotherapy #CytokineReleaseSyndrome #PharmaLeadership #ClinicalResearch #DrugDevelopment #PharmaNews #ProactiveLondon #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) Chief Legal Officer John McEvoy speaks to Thomas Warner from Proactive London about how he intends to carry out his new role, having joined Poolbeg on January 1st. McEvoy details his transition from commercial-stage pharmaceutical company Amryt Pharma, saying that he was drawn to Poolbeg's potential for growth and innovation. His decision was influenced by previous encounters with Poolbeg's leadership team, notably Chairman Cathal Friel, and the company's promising pipeline, including its POLB 001 oncology asset. McEvoy's tenure at Amryt was marked by significant accomplishments, including a $1.5 billion valuation and his recognition as Life Sciences Lawyer of the Year in 2023. He says his experience in guiding a high-growth, NASDAQ-listed company and expertise in multiple legal jurisdictions played a pivotal role in his success. At Poolbeg, McEvoy aims to leverage his diverse legal background and strategic insight to drive the company's growth. He emphasises the importance of a holistic approach as a Chief Legal Officer, contributing not just legal expertise but also strategic guidance and leadership across the organisation. McEvoy's focus will be on developing Poolbeg's intellectual property portfolio and exploring market opportunities for the company's assets, with an eye on near-term revenue generation and pipeline expansion. #PoolbegPharma #JohnMcEvoy #PharmaceuticalIndustry #Biotech #LegalLeadership #PharmaInnovation #DrugDevelopment #OncologyResearch #LifeSciences #BiopharmaGrowth #PharmaPipeline #PharmaStrategy #HealthcareLeadership #CorporateLaw #IntellectualProperty #MarketExpansion #Pharmaceuticals #LegalInsights #ExecutiveInterview #BusinessStrategy #HealthcareIndustry #PharmaLeadership #BiotechInnovation #PharmaTrends #HealthcareTrends #PharmaceuticalLaw #ProactiveInvestors #pharma #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company announced some progress on lead asset, POLB 001. Skillington, fresh from the JPMorgan conference in San Francisco, announces "very positive" in vivo data for POLB 001, showing efficacy in reducing cancer immunity-induced cytokine release syndrome (CRS). This development bolsters the company's hypothesis and strengthens their patent applications in this area. Skillington highlighted POLB 001's dual role as both a preventative and a treatment for CRS, a notable advancement since no approved preventative therapies currently exist for this condition. This development could significantly benefit patients and ease healthcare system burdens. With its potential as an oral therapy, POLB 001 stands out in a market dominated by injectable treatments, offering the convenience of at-home administration. Further enhancing Poolbeg's strategic position, the addition of David Allmond as Chief Business Officer and the formation of a scientific advisory board have provided valuable insights for program positioning and market needs. Finally, Skillington discusses the immense market potential for POLB 001, estimating it at $1 billion, particularly in treating multiple myeloma, high-grade lymphoma, and acute lymphoblastic leukemia. #PoolbegPharma #JeremySkillington #HealthcareInnovation #CancerTreatment #Immunotherapy #POLB001 #CytokineReleaseSyndrome #PharmaceuticalIndustry #BiotechNews #MedicalResearch #ProactivInterview #CancerTherapyAdvancements #HealthTech #PharmaLeaders #Biotechnology #Oncology #PharmaNews #MedicalBreakthrough #ClinicalTrials #HealthcareTrends #InnovativeMedicine #ProactiveInvestors #poolbeg #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

(Watch the video interview HERE) Vox Markets talks to Poolbeg Pharma #POLB CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy. 0:30 How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS 1:36 The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting 3:12 How an Independent Advisory Board is supportive of POLB 001's potential to both prevent and treat cancer immunotherapy-induced CRS. 5:02 Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg

Poolbeg Pharma #POLB CEO Jeremy Skillington talks to Vox Markets about a year which has seen the global pharma industry take a keen interest in the company's innovative AI-led approach.

(Watch the video interview HERE) Jeremy Skillington, CEO of Poolbeg Pharma #POLB, talks Vox Markets through the latest positive results of its lab-based, AI led analysis of its RSV drug candidates 00:28 Details of the latest results of lab-based analysis of RSV drug candidates. 01:24 How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery. 2:41 The importance of the data quality offered by human challenge models in lab-base analysis. 4:35 The growing importance of AI in drug discovery, and how Poolbeg's leading position should open up partnering opportunities with biopharma groups.

For many private European biotechs, flat or down valuations have become the new normal as they struggle to raise money despite having quality science, +ND Capital's Dani Bach said on a special edition of the BioCentury This Week podcast featuring takeaways from the 2023 Bio€quity Europe conference in Dublin. Investors, he said, are flocking to a handful of outsize fundraising rounds out of fear. In conversation Monday with Jeff Cranmer and Stephen Hansen of BioCentury and Poolbeg's Jeremy Skillington, Bach described a bipolar fundraising environment in which the “bulk of companies are struggling for money and a few are getting massive amounts of money even beyond their wild expectations.” Bach, Skillington and BioCentury's editors also discuss Ireland's burgeoning biotech ecosystem, Europe's biopharma hubs and the performance of U.K.'s biotechs listed on the London Stock Exchange. This episode is sponsored by Jeito Capital.

Poolbeg Pharma (OTCQB: POLBF) is a clinical stage infectious disease pharmaceutical company with a capital light clinical model which is looking to develop multiple products faster and more cost effectively than the conventional biotech model. CEO Jeremy Skillington joins us to discuss how the Covid-19 pandemic has impacted the company's research on infectious diseases. View Podcast Transcript for Poolbeg Pharma